Revenue
2023
2024
2025
Telix Pharmaceuticals Ltd (TLX)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $803.8M | $516.6M | $333.0M |
| Gross profit | $426.4M | $336.2M | $209.5M |
| Research & development | $171.2M | $127.9M | $85.3M |
| Operating income | $29.8M | $55.2M | $11.0M |
| EBITDAderived | $51.3M | $60.0M | $15.5M |
| Net income | −$7.1M | $33.7M | $4.2M |
| Basic EPSper diluted share | -$0.02 | $0.10 | $0.01 |
| Diluted EPSper diluted share | -$0.02 | $0.10 | $0.01 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 29, 2026Form 4 | Behrenbruch ChristianMD & Group CEO | BuyOrdinary Shares · indirect | 33.4K | $14.87 | $497.2K | 20.74M |
| Apr 28, 2026Form 4 | Behrenbruch ChristianMD & Group CEO | BuyOrdinary Shares · indirect | 34.5K | $14.48 | $499.6K | 20.71M |